Login to Your Account


Amgen PCSK9 antibody reduces cholesterol in Phase III study

By Catherine Shaffer
Staff Writer

Tuesday, December 17, 2013

Amgen Inc. is hot on the heels of Regeneron Pharmaceuticals Inc., reporting that its monoclonal antibody targeting PCSK9, evolocumab, reduced low-density lipoprotein cholesterol (LDL-C) in a 12-week Phase III trial. Thousand Oaks, Calif.-based Amgen did not disclose the numeric results of the trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription